# Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
Robert F. Hofmann	10/06/2008

#### RECEIVING PARTY DATA

Name:	Torquin, LLC		
Street Address:	5900 SW Parkway		
Internal Address:	Suite 520		
City:	Austin		
State/Country:	TEXAS		
Postal Code:	78735		

#### PROPERTY NUMBERS Total: 11

Property Type	Number
Patent Number:	6790463
Patent Number:	6884797
Patent Number:	7414044
Application Number:	11059947
Application Number:	11074192
Application Number:	11074191
Application Number:	11125996
Application Number:	11125773
Application Number:	11125932
Application Number:	11158997
Application Number:	11158514

#### **CORRESPONDENCE DATA**

Fax Number: (214)661-6870

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

**PATENT** 

REEL: 021679 FRAME: 0403

\$440.00

500676275

Phone: 214-953-5959

Email: dpepper@jw.com

Correspondent Name: T. Ling Chwang

Address Line 1: 901 Main Street

Address Line 2: Suite 6000

Address Line 4: Dallas, TEXAS 75202

,

ATTORNEY DOCKET NUMBER: 103336.2

NAME OF SUBMITTER: T. Ling Chwang

**Total Attachments: 9** 

source=Assignment, Torquin, all#page1.tif source=Assignment, Torquin, all#page2.tif source=Assignment, Torquin, all#page3.tif source=Assignment, Torquin, all#page4.tif source=Assignment, Torquin, all#page5.tif source=Assignment, Torquin, all#page6.tif source=Assignment, Torquin, all#page7.tif source=Assignment, Torquin, all#page8.tif

source=Assignment, Torquin, all#page9.tif

#### **AMENDED ASSIGNMENT**

For good and valuable consideration, I, Robert F. Hofmann, hereinafter referred to as Assignor, hereby sell, assign and transfer to Torquin, LLC, having its principal place of business at 5900 SW Parkway, Suite 520, Austin, Texas 78735, hereinafter referred to as Assignee, my entire right, title and interest in and to the patents and patent applications listed on Schedules 1, 2, 3 and 4 attached hereto, and the inventions disclosed therein; and all divisional, continuing, substitute, renewal, reissue, improvements, and all other applications for Letters Patent which have been or shall be filed in the United States and in all foreign countries on said inventions; and in all foreign countries on said inventions;

Assignor agrees that Assignee may apply for and receive Letters Patents for said inventions in its own name;

Assignor agrees that, at the request of the Assignee and, without charge to but at the expense of said Assignee, Assignor will carry out in good faith the intent and purpose of this Assignment; execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to Assignee all facts known to the undersigned relating to said inventions and the history thereof; and generally do everything possible which Assignee shall consider desirable for aiding in securing and maintaining proper patent protection for said inventions and for vesting title to said invention, and all applications for patents and all patents on invention in said Assignee;

Covenant with Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

Assignor warrants and represents to Assignee that, to the best of his knowledge, Letter Patents which have already been formally granted, issued and/or published were properly filed in their respective jurisdiction. Assignor does not warrant or represent to Assignee, or any other person or entity, that the Letter/Patents are in good standing or that any other related patent applications are properly filed or pending in any jurisdiction.

This Assignment will be made effective as of the 9th day of October 2008.

<b>ASSI</b>	GN	Ol	3
<b>A221</b>	GIN	U	1

	Robert F. Hofmann
	1000tt 1. Homani
STATE OF TEXAS	§ 8
COUNTY OF TRAVIS	§ § §
	8, before me personally came Robert F. Hofmann, herein and who executed the foregoing instrument,
	Notary Public
Seal	My Commission Expires:
The undersigned accepts the foregoin	ASSIGNED  Name: Craig Fryar Title: President Torquin, LLC
STATE OF TEXAS COUNTY OF TRAVIS	§ § §
On this day of October 2008, me to be the individual described herein acknowledged execution of the same.	before me personally came Craig Fryar, known to and who executed the foregoing instrument, and Notary Public My Commission Expires:
- ·	CINDY FOREMAN Notary Public, State of Te My Commission Expire July 06, 2012

	0
STATE OF TEXAS	§ 8
COUNTY OF TRAVIS	§ § §
	2008, before me personally came Robert F. Hofmann, bed herein and who executed the foregoing instrument,  Notary Public
Seal	My Commission Expires: 7-74-09
The undersigned accepts the foreg	oing assignment as of the day of October 2008.  ASSIGNEE  Name: Craig Fryar Title: President
	Torquin, LLC
STATE OF TEXAS	§ § §
COUNTY OF TRAVIS	§ 8
	008, before me personally came Craig Fryar, known to ein and who executed the foregoing instrument, and
	Notary Public
Seal	My Commission Expires:

ASSIGNOR

### **United States Patents**

REF. NO.	PATENT NO.	ISSUE DATE	TITLE
TORQ-0002	6,790,463	09/14/04	USES OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN ARTERIOSCLEROSIS
TORQ-0001	6,884,797	04/26/05	TARGETED OXIDATIVE THERAPEUTIC FORMULATION
TORQ-0004	7,414,044	08/19/08	USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN TREATMENT OF DIABETES AND OBESITY
ABANDONED	5,817,630	10/06/98	GLUTATHIONE ANTIOXIDANT EYE DROPS

# **United States Patent Applications**

REF. NO.	SERIAL NO.	FILE DATE	TITLE
TORQ-0005	11/059,947	02/17/05	USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN TREATMENT OF VIRAL DISEASES
TORQ-0001D1	11/074,192	03/07/05	TARGETED OXIDATIVE THERAPEUTIC FORMULATION
TORQ-0001D2	11/074,191	03/07/05	TARGETED OXIDATIVE THERAPEUTIC FORMULATION
TORQ-0006	11/125,996	05/10/05	USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN TREATMENT OF CANCER
TORQ-0007	11/125,773	05/10/05	USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN BONE REGENERATION
TORQ-0008	11/125,932	05/10/05	USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN TREATMENT OF AGERELATED MACULAR DEGENERATION
TORQ-0009	11/158,997	06/22/05	USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN TREATMENT OF BURNS
TORQ-0010	11/158,514	06/22/05	USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN ENDODONTIC TREATMENT

# Foreign Patents

REF. NO	COUNTRY	PATENT NO.	ISSUE	TITLE
			DATE	
TORQ-0001SG	Singapore	99581	01/27/06	TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
TORQ-0002SG	Singapore	100421	01/27/06	USES OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN ARTERIOSCLEROSIS
TORQ-0008 DE	Germany	602005005666.1	03/26/08	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF AGE-
				RELATED MACULAR
				DEGENERATION
TORQ-0008 FR	France	1747017	03/26/08	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF AGE-
				RELATED MACULAR
				DEGENERATION
TORQ-0008 GB	Great Britain	1747017	03/26/08	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF AGE-
				RELATED MACULAR
				DEGENERATION
TORQ-0009 DE	Germany	602005009195.5	08/20/08	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
		***************************************		IN TREATMENT OF BURNS
TORQ-0009 GB	Great Britain	1768661	08/20/08	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF BURNS
TORQ-0009 FR	France	1768661	08/20/08	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF BURNS

### Foreign Patent Applications

REF. NO.	COUNTRY	SERIAL NO.	FILE	TITLE
		SERIAL NO.	DATE	TILE
TORQ-0005CA	Canada	2,556,437	02/17/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION IN
				TREATMENT OF VIRAL DISEASES
TORQ-0004CA	Canada	2,565,363	05/05/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF DIABETES
				AND OBESITY
TORQ-0008CA	Canada	2,566,190	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF AGE-
				RELATED MACULAR
				DEGENERATION
TORQ-0007CA	Canada	2,566,188	05/10/05	USE OF TARGETED OXIDATIVE
			-	THERAPEUTIC FORMULATION
				IN BONE REGENERATION
TORQ-0006CA	Canada	2,566,180	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF CANCER
TORQ-0010CA	Canada	2,571,569	06/22/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN ENDODONTIC TREATMENT
TORQ-0009CA	Canada	2,570,754	06/22/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF BURNS
TORQ-0001CN	China	02808703.8	03/22/02	TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
TORQ-0002CN	China	02810607.5	03/22/02	USES OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN ARTERIOSCLEROSIS
TORQ-0005CN	China	200580012320.8	02/17/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION IN
				TREATMENT OF VIRAL DISEASES
TORQ-0004CN	China	200580022437.4	05/05/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF DIABETES
				AND OBESITY
TORQ-0008CN	China	200580023354.7	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF AGE-
				RELATED MACULAR
				DEGENERATION
TORQ-0007CN	China	200580023281.1	05/10/05	USE OF TARGETED OXIDATIVE
-				THERAPEUTIC FORMULATION
				IN BONE REGENERATION

REF. NO.	COUNTRY	SERIAL NO.	FILE DATE	TITLE
TORQ-0006CN	China	200580023352.8	05/10/05	USE OF TARGETED OXIDATIVE
Torre outser.	China	200300023332.0	05/10/05	THERAPEUTIC FORMULATION
				IN TREATMENT OF CANCER
TORQ-0010CN	China	200580022450.X	06/22/05	USE OF TARGETED OXIDATIVE
10110	J. J	20000022:00:71	00/22/03	THERAPEUTIC FORMULATION
				IN ENDODONTIC TREATMENT
TORQ-0009CN	China	200580021015.5	06/22/05	USE OF TARGETED OXIDATIVE
			00/22/03	THERAPEUTIC FORMULATION
				IN TREATMENT OF BURNS
TORQ-0001EP	Europe	02757804.6	03/22/02	TARGETED OXIDATIVE
	•			THERAPEUTIC FORMULATION
TORQ-0002EP	Europe	02728556.8	03/22/02	USES OF TARGETED OXIDATIVE
	*			THERAPEUTIC FORMULATION
				IN ARTERIOSCLEROSIS
TORQ-0004EP	Europe	05746254.1	05/05/05	USE OF TARGETED OXIDATIVE
	•			THERAPEUTIC FORMULATION
				IN TREATMENT OF DIABETES
				AND OBESITY
TORQ-0007EP	Europe	05747999.0	05/10/05	USE OF TARGETED OXIDATIVE
	-			THERAPEUTIC FORMULATION
				IN BONE REGENERATION
TORQ-0006EP	Europe	05747977.6	05/10/05	USE OF TARGETED OXIDATIVE
	•			THERAPEUTIC FORMULATION
				IN TREATMENT OF CANCER
TORQ-0010EP	Europe	05767601.7	06/22/05	USE OF TARGETED OXIDATIVE
	-			THERAPEUTIC FORMULATION
				IN ENDODONTIC TREATMENT
TORQ-0004IN	India	3620/KOLNP/2006	05/05/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF DIABETES
				AND OBESITY
TORQ-0008IN	India	3668/KOLNP/2006	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF AGE-
				RELATED MACULAR
				DEGENERATION
TORQ-0007IN	India	3660/KOLNP/2006	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
		·		IN BONE REGENERATION
TORQ-0006IN	India	3661/KOLNP/2006	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF CANCER
TORQ-0010IN	India	282/KOLNP/2007	06/22/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN ENDODONTIC TREATMENT
TORQ-0009IN	India	279/KOLNP/2007	06/22/05	USE OF TARGETED OXIDATIVE
1				THERAPEUTIC FORMULATION
			***************************************	IN TREATMENT OF BURNS

REF. NO.	COUNTRY	SERIAL NO.	FILE	TITLE
TORQ-0004KR	S. Korea	10-2006-7025692	<b>DATE</b> 05/05/05	USE OF TARGETED OXIDATIVE
			03/03/03	THERAPEUTIC FORMULATION
				IN TREATMENT OF DIABETES
				AND OBESITY
TORQ-0008KR	S. Korea	10-2006-7025820	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF AGE-
				RELATED MACULAR
				DEGENERATION
TORQ-0007KR	S. Korea	10-2006-7025981	05/10/05	USE OF TARGETED OXIDATIVE
	E.			THERAPEUTIC FORMULATION
mono constant				IN BONE REGENERATION
TORQ-0006KR	S. Korea	10-2006-7025946	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
CIOD C. AAAATT				IN TREATMENT OF CANCER
TORQ-0010KR	S. Korea	10-2007-7001615	06/22/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
GIOD O ASSOCIA				IN ENDODONTIC TREATMENT
TORQ-0009KR	S. Korea	10-2007-7001656	06/22/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
TORONO	ļ <u></u>			IN TREATMENT OF BURNS
TORQ-0005	Singapore	200706058-5	02/17/05	USE OF TARGETED OXIDATIVE
SG/D1				THERAPEUTIC FORMULATION
				IN TREATMENT OF VIRAL
TOPO MARC	0:	200607620		DISEASES
TORQ-0004SG	Singapore	200607638-4	05/05/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF DIABETES
TORQ-0008SG	Cinconon	200607021.6	05/10/05	AND OBESITY
10KQ-00065G	Singapore	200607821-6	05/10/05	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
				IN TREATMENT OF AGE-
				RELATED MACULAR
TORQ-0007SG	Singapore	200607820-8	05/10/05	DEGENERATION USE OF TARGETED OVER A TIME
1010 000/50	Singapore	200007620-6	03/10/03	USE OF TARGETED OXIDATIVE
				THERAPEUTIC FORMULATION
TORQ-0006SG	Singapore	200607819-0	05/10/05	IN BONE REGENERATION USE OF TARGETED OXIDATIVE
10110 00000	Singapore	200007819-0	03/10/03	THERAPEUTIC FORMULATION
TORQ-0010SG	Singapore	200608937-9	06/22/05	IN TREATMENT OF CANCER USE OF TARGETED OXIDATIVE
001000	Bupore	200000737*7	00/22/03	THERAPEUTIC FORMULATION
				IN ENDODONTIC TREATMENT
TORQ-0009SG	Singapore	200608938-7	06/22/05	USE OF TARGETED OXIDATIVE
2224 20000	~gupoio	200000736-7	00122103	THERAPEUTIC FORMULATION
				IN TREATMENT OF BURNS
		L		IN TREATMENT OF DURING

PATENT REEL: 021679 FRAME: 0413

RECORDED: 10/15/2008